<DOC>
	<DOCNO>NCT00469560</DOCNO>
	<brief_summary>Open label , single arm study Deferasirox treatment MDS patient chronic transfusional hemosiderosis . Patients receive daily oral dosis Deferasirox order eliminate quantity iron administer transfusion , need , reduce overload already present iron . After screen phase patient evaluate accord eligibility criterion , one year treatment phase foresee monthly visit evaluate safety efficacy sign .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Deferasirox MDS</brief_title>
	<detailed_description>It widely show appropriate chelating therapy chronic anemias transfusion dependent prevent overstock iron reduce already exist overstock reducing , , co-morbidity improve survival . In particular , author show MDS affect patient undergo intensive chelate therapy deferoxamine haematological recovery reduction need transfusion . With present study , plan evaluate safety efficacy therapy new oral chelating Deferasirox MDS patient transfusional hemosiderosis . This open label , single arm study Deferasirox treatment MDS patient chronic transfusional hemosiderosis . Patients receive daily oral dosis Deferasirox order eliminate quantity iron administer transfusion , need , reduce overload already present iron . After screen phase patient evaluate accord eligibility criterion , one year treatment phase foresee monthly visit evaluate safety efficacy sign .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients , male female , low intermediate I risk ( IPSS score ) Myelodysplastic syndrome transfusioninduced hemosiderosis . Age &gt; =18 year Patients never receive chelation therapy receive therapy Desferal day wash Medical history least 20 blood transfusion ( equivalent 100 ml/kg red cell concentrate ) . Availability data concern blood transfusion 12 week screen Serum ferritin &gt; = 1000 Âµg/L least twice ( least 2 week interval 2 analysis ) year screen Life expectancy &gt; 12 month Availability least 3 complete blood count ( transfusion ) 12 week screen Diagnosis different MDS ( i.e . myelofibrosis ) Severe renal impairment ( creatinine clearance &lt; 60 ml/min ) ALT/AST &gt; 500 U/L Active B and/or C hepatitis Patients treat past 4 week experimental drug MDS ( include thalidomide , azacitidine , arsenic trioxide ) . These patient become eligible `` wash '' least 4 week Concomitant treatment another ironchelating agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>Chronic transfusional hemosiderosis</keyword>
	<keyword>Deferasirox</keyword>
</DOC>